BRAF and cancer: A retrospective cohort study conducted in multiple facilities in the Netherlands demonstrated that the BRAF mutation is an independent prognostic factor for overall survival (OS) (hazard ratio (HR) 2.22, 95% confidence interval (CI) 1.25–4.00), disease-free survival (DFS) (HR 2.33, 95% CI 1.22–4.55), and cancer-specific survival (CCS) (HR 2.13, 95% CI 1.01–4.55) in Stage II/III CRC by multivariate analysis [44].